Cytokinetics (FRA:KK3A) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KK3A Cytokinetics Inc FRA:KK3A
53 GF Score
Price €58.34
GF Value €187.17
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cytokinetics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

FRA:KK3A
53GF Score
Cytokinetics Inc FRA:KK3A
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cytokinetics (FRA:KK3A) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €58.34 is trading 68.8% below its estimated GF Value™ of €187.17. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for FRA:KK3A:

  • Interest Expense (Positive):
  • GF Value™: €187.17 vs. price of €58.34 (68.8% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the FRA:KK3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytokinetics Business Description

Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company based in South San Francisco, California, focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as treatments for diseases in which muscle performance is compromised. Its pipeline targets cardiovascular and neuromuscular conditions, including hypertrophic cardiomyopathy, heart failure, amyotrophic lateral sclerosis, and spinal muscular atrophy. Aficamten, a cardiac myosin inhibitor, is its lead cardiovascular candidate for hypertrophic cardiomyopathy; omecamtiv mecarbil is a cardiac myosin activator; and reldesemtiv and other skeletal muscle activators target neuromuscular disorders. The company conducts clinical trials in the United States and internationally, often in collaboration with partners and academic centers. It has no significant marketed products and generates revenue primarily through research collaborations, licensing agreements, and milestone payments rather than product sales, while funding operations largely through equity financings and partnership proceeds.
53GF Score

Get the complete analysis for FRA:KK3A

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.34
Price
€187.17
GF Value